SEC Form 4 · accession 0001209191-18-024449
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mina Kim
Officer — Senior VP & General Counsel
Period of report
Apr 9, 2018
Accepted (ET)
Apr 9, 2018 · 8:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 9, 2018 | A | 42,500 | $0.00 | A | 42,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $36.00 | Apr 9, 2018 | A | 70,000 | A | — | Apr 8, 2025 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F125% of the shares subject to restricted stock units vest on April 9, 2019 and the remaining shares vest in equal annual installments over the following 3 years.
- F225% of the shares subject to the option vest on April 9, 2019 and the remaining shares vest in equal monthly installments over the following 36 months.